In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer
Authors:
Open Access
- 21 September 2014
- journal article
- research article
- Published by Wiley in Advances in Bioinformatics
- Vol. 2014, 1-7
Abstract
K-ras is an oncogenic GTPase responsible for at least 15–25% of all non-small cell lung cancer cases worldwide. Lung cancer of both types is increasing with an alarming rate due to smoking habits in Malaysia among men and women. Natural products always offer alternate treatment therapies that are safe and effective. Typhonium flagelliforme or Keladi Tikus is a local plant known to possess anticancer properties. The whole extract is considered more potent than individual constituents. Since K-ras is the key protein in lung cancer, our aim was to identify the constituents of the plant that could target the mutated K-ras. Using docking strategies, reported potentially active compounds of Typhonium flagelliforme were docked into the allosteric surface pockets and switch regions of the K-ras protein to identify possible inhibitors. The selected ligands were found to have a high binding affinity for the switch II and the interphase region of the ras-SOS binding surface.Keywords
This publication has 31 references indexed in Scilit:
- Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian PatientsJournal of Thoracic Oncology, 2013
- The genetics and biology of KRAS in lung cancerChinese Journal of Cancer, 2013
- Apoptosis Effect of Girinimbine Isolated fromMurraya koenigiion Lung Cancer CellsIn VitroEvidence-Based Complementary and Alternative Medicine, 2013
- Ras in Cancer and Developmental DiseasesGenes & Cancer, 2011
- Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extensionClinical Biochemistry, 2010
- KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung CancerClinical Cancer Research, 2007
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- Overview of Cancer in MalaysiaJapanese Journal of Clinical Oncology, 2002
- Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain.Proceedings of the National Academy of Sciences, 1990
- Molecular Switch for Signal Transduction: Structural Differences Between Active and Inactive Forms of Protooncogenic ras ProteinsScience, 1990